Skip to main content
. Author manuscript; available in PMC: 2022 Feb 1.
Published in final edited form as: Gastroenterology. 2020 Oct 8;160(3):831–846.e10. doi: 10.1053/j.gastro.2020.10.002

Figure 5. Large scale-organoid based toxicity (LoT) screen identifies compounds with toxic potential.

Figure 5.

A. Schematic of the DILI screen workflow with image of quantification strategy for CLF and cell viability.

B. Representative images of 384-well drug screen plate with quantification of CLF at 24 hours. CLF mono-fluorescence converted to intensity plot by imageJ. Right upper image: negative compound (sucrose), right bottom image: positive compounds (CSA). See Supplementary Table 1.

C. Violin plot of CLF intensity in HLO treated with compounds relative to control.

D. Scatter plot of the viability and CLF intensity. Sen: sensitivity (true positive / true positive + false negative), Spe: specificity (true negative / true negative + false positive). Circle dots: the data of DILI positive compounds. Triangle dot: the data of DILI negative compounds. n = 5.

E. CLF intensity of representative drugs categorized into Negative and Cholestatic groups.